Which Type of Cancer Patients Are More Susceptible to the SARS-COX-2: Evidence From a Meta-Analysis and Bioinformatics Analysis

Crit Rev Oncol Hematol. 2020 Jun 15;153:103032. doi: 10.1016/j.critrevonc.2020.103032. Online ahead of print.

Abstract

Objective: Numerous studies have reported that patients with cancer seem to be more likely to be diagnosed with COVID-19. However, it is still unknown the prevalence of different types of cancer in patients with COVID-19. Therefore, this study will explore which type of cancer patients are more susceptible to the SARS-COX-2.

Methods: Eligible studies were identified by searching several electronic databases for relevant studies published before April 28, 2020. The language was restricted to English or Chinese. The meta-analysis was performed using Stata 12.0. The GEPIA database evaluated the expression of SARS-COX-2 infection key genes in different types of normal and tumor samples.

Results: A total of 6 studies, including 205 patients, were identified to be eligible for this meta-analysis. Among the cancer patients infected by SARS-COX-2, the proportion of patients with the lung, colorectal, breast, esophagus, bladder, pancreatic and cervical cancer were 24.7 %, 20.5 %, 13.0 %, 7.6 %,7.3 %,6.1 %,and 6.0 %, respectively. These findings were also corroborated by the results of the GEPIA database.

Conclusion: Compared with other types of cancer, lung cancer and colorectal cancer are more susceptible to SARS-COX-2 infection.

Keywords: COVID-19; Cancer; Meta-analysis; SARS-CoV-2.

Publication types

  • Review